Literature DB >> 1446493

Human pleural effusions are rich in matrix metalloproteinases.

A N Hurewitz1, S Zucker, P Mancuso, C L Wu, B Dimassimo, R M Lysik, D Moutsiakis.   

Abstract

We identified and characterized type IV collagenase and gelatinase activity in pleural fluid from 32 patients. The capacity to substantially degrade type IV collagen was demonstrated in every pleural sample. Comparable results were also noted for the degradation of a radiolabeled gelatin substrate. Gelatin gel zymography of the pleural fluids revealed two prominent zones of lysis at 66 kDa and 92 kDa. These were identified by specific polyclonal antibodies as human matrix metalloproteinases MMP-2 and MMP-9. The concentration of MMP-2 in pleural fluid, as measured by enzyme-linked immunoassay, averaged 1,622 ng/ml whereas those of MMP-9 were 210 ng/ml. Substrate degradation activity was compared in both serum and pleural fluid from three patients and found to be similar. In serum this enzymatic activity was primarily due to MMP-9 whereas in pleural fluid, the predominant gelatinase was MMP-2. This was confirmed by immunoassay that showed that MMP-2 levels were two to five times higher in pleural fluid than in serum. We conclude that substantial amounts of MMP-2 and, to a lesser degree, MMP-9 are present in pleural effusions. The bioactivity and the immunoactivity of these enzymes did not help to distinguish among pleural fluids characterized as transudates, nonmalignant exudates, or malignant exudates. The differences in the distribution of these enzymes in pleural fluid and blood suggest that their presence is not due simply to the ultrafiltration of plasma, but rather to synthesis by the resident cells at the pleural surfaces.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446493     DOI: 10.1378/chest.102.6.1808

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis.

Authors:  T Hayashi; W G Stetler-Stevenson; M V Fleming; N Fishback; M N Koss; L A Liotta; V J Ferrans; W D Travis
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

Review 3.  Matrix metalloproteases and lung disease.

Authors:  C M O'Connor; M X FitzGerald
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

4.  Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus.

Authors:  A Faber-Elmann; Z Sthoeger; A Tcherniack; M Dayan; E Mozes
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

5.  Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.

Authors:  Joelle Hillion; Lisa J Wood; Mita Mukherjee; Raka Bhattacharya; Francescopaolo Di Cello; Jeanne Kowalski; Ossama Elbahloul; Jodi Segal; John Poirier; Charles M Rudin; Surajit Dhara; Amy Belton; Biju Joseph; Stanley Zucker; Linda M S Resar
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

6.  Growth factor modulation of rat pleural mesothelial cell mitogenesis and collagen synthesis. Effects of epidermal growth factor and platelet-derived factor.

Authors:  M W Owens; S A Milligan
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

7.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions.

Authors:  Lisete Ribeiro Teixeira; Murilo B Dias; Roberta K B Sales; Leila Antonangelo; Vanessa A Alvarenga; Juliana Puka; Evaldo Marchi; Milena Marques Pagliarelli Acencio
Journal:  Lung       Date:  2016-09-27       Impact factor: 2.584

9.  Decreased proinflammatory cytokines production in children with complicated parapneumonic pleural effusion after intrapleural fibrinolytic treatment.

Authors:  Jieh-Neng Wang; Jyh-Wei Shin; Tsuey-Yu Chang; Jiu-Yao Wang; Jing-Ming Wu
Journal:  Inflammation       Date:  2009-12       Impact factor: 4.092

10.  Influence of aging, localization, glucocorticoids and isotretinoin on matrix metalloproteases 2 (MMP-2) and 9 (MMP-9) in suction blister fluids.

Authors:  M Kylmäniemio; P Autio; A Oikarinen
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.